Company:Life Biosciences
From HandWiki
| Industry |
|
|---|---|
Key people | David A. Sinclair |
| Website | lifebiosciences |
Life Biosciences is a Boston based biopharmaceutical company focused on developing epigenetic medicines for aging and age-related diseases. The company was founded in 2017 by Harvard Medical School professor David Sinclair. In early 2026, the US Food and Drug Administration cleared Life Biosciences to begin testing its invesitgational, adeno-associated viral vector drug, ER-100, for treatment of optic neuropathies including certain types of glaucoma and non-arteritic anterior ischemic optic neuropathy. The drug is proposed to work by expressing Yamanaka factors to alter DNA methylation states.[1][2][3][4]
References
- ↑ Quiroz-Gutierrez, Marco (30 January 2026). "As billionaires chase immortality, this startup cofounded by a Harvard genetics professor gets FDA approval for the first partial de-aging human trial". Fortune. https://fortune.com/2026/01/30/billionaires-longevity-aging-fda-human-clinical-trial-life-biosciences-jerry-mclaughlin-david-sinclair-harvard-science/.
- ↑ McMahon, Raphael (30 October 2025). "This Longevity Startup Is Bringing Anti-Aging Gene Therapy to Human Trials". The New York Observer. https://observer.com/2025/10/this-longevity-startup-is-bringing-anti-aging-gene-therapy-to-human-trials/.
- ↑ Weisman, Robert (1 December 2018). "Fountains of youth: Biotech startups emerge from stealth mode to ‘take on aging’". Boston Globe. https://www.bostonglobe.com/metro/2018/12/01/fountains-youth-biotech-startups-emerge-from-stealth-mode-take-aging/qTXKvfu3uJLoMxteLI7HxM/story.html.
- ↑ "FDA go-ahead to test cellular rejuvenation therapy in humans". Nature (journal). 17 February 2026. doi:10.1038/s41587-026-03037-z. https://www.nature.com/articles/s41587-026-03037-z. Retrieved 19 March 2026.
 |  |
